Specialty
Certifications
Nephrology
American Board of Internal Medicine
Clinical Focus
Education
DO, University of Kansas
Residency, Internal Medicine
Cleveland Clinic FoundationFellowship, Nephrology
Cleveland Clinic Foundation
Biography
Dr. Olin is a Professor of Medicine at the Icahn School of Medicine at Mount Sinai and Director of Vascular Medicine and the Vascular Diagnostic Laboratory in the Zena and Michael A. Wiener Cardiovascular Institute and Marie-Josée and Henry R. Kravis Center for Cardiovascular Health of The Mount Sinai Medical Center.
His clinical expertise involves noncoronary vascular diseases such as fibromuscular dysplasia, peripheral artery disease, carotid artery disease, renal artery disease, venous thromboembolic disease and less common vascular diseases. He is an international leader in vascular ultrasound and has developed new noninvasive techniques to evaluate patients for renal artery stenosis and treat catheter associated pseudoaneurysms.
Dr. Olin is an internationally recognized expert in the field of Vascular Medicine. He has held numerous leadership positions and has been at the forefront of establishing Vascular Medicine as a distinct subspecialty of Cardiovascular Medicine. He was instrumental in the formation of the American Board of Vascular Medicine, the first ever board examination in this specialty. Dr. Olin is a past president of the Society for Vascular Medicine and recently has been awarded the highest honor from that society, Master of the Society for Vascular Medicine. Dr Olin received the inaugural Jess R Young, M.D. teaching award from the Society for Vascular Medicine and in 2013 he received the Simon Dack, M.D. teaching award from the fellows at the Zena and Michael A. Wiener Cardiovascular Institute and Marie-Josée and Henry R. Kravis Center for Cardiovascular Health of the Mount Sinai Medical Center.
He is a past member of the peripheral vascular disease committee of the American College of Cardiology and past Chair of the Interdisciplinary Working Group on Atherosclerotic Peripheral Vascular Disease of the American Heart Association. He played an instrumental role in the transformation of this working group to that of a Council of the American Heart Association. He was a member of the highest-ranking scientific committee of the American Heart Association, the Scientific Advisory and Coordinating Committee. He was a member of the Board of Directors of the AmericanBoard of Vascular Medicine and is one of four physicians selected to direct a task force leading to an examination in the certification entitled Registered Physician in Vascular Ultrasound (RPVI).
Dr. Olin has been involved in clinical research involving fibromuscular dysplasia, peripheral artery disease, renal artery disease and carotid artery disease. He is the Mount Sinai Principal Investigator of the NIH sponsored CORAL trial studying the effect of stents in patients with atherosclerotic renal artery stenosis and is on the steering committee for an international study using placental stem cells to treat patients with intermittent claudication and critical limb ischemia. He is on the international steering committee for the EUCLID Trial to determine the most effective antiplatelet regimen in patients with peripheral artery disease. He is the PI for the United States Registry for Fibromuscular Dysplasia and Chair of the Medical Advisory Board of the Fibromuscular Dysplasia Society of America. He is the Director for the Mount Sinai Heart Center for Fibromuscular Dysplasia Care and Research.
Dr. Olin has authored more than 200 scientific papers in the peer review literature, 3 books and more than 70 book chapters. He has served on many writing committees of the American College of Cardiology and American Heart Association. He chaired the writing committee on Performance Measures in Peripheral Arterial Disease, and the Scientific Statement from the American Heart Association on fibromuscular dysplasia. He has published in the New England Journal of Medicine, Circulation, Journal of the American Medical Association, Journal of the American College of Cardiology, Journal of Vascular Surgery and Vascular Medicine to name a few. He is an Associate Editor of the journal Vascular Medicine, an incoming Associate Editor for the Journal of the American College of Cardiology and Editor of the textbook Peripheral Vascular Diseases.
After receiving his medical degree from the University of Health Sciences in Kansas City, Missouri, he completed his residency and fellowship at the Cleveland Clinic Foundation. In 2003 he came to the Mount Sinai School of Medicine as Director of Vascular Medicine and Co-director of the Vascular Diagnostic Laboratory where he has developed a comprehensive clinical, educational and research program in Vascular Medicine.
In The News: Dr. Jeffrey Olin discusses fibromuscular dysplasia in the The Daily News feature The Daily Check-Up. His program on fibromuscular dysplasia is discussed in the Wall Street Journal article on "The Rare Disease that Isn't" http://online.wsj.com/news/articles/SB124605981966763611
Awards
2014 -
Associate Editor, Journal of the American College of Cardiology
American College of Cardiology2013 -
Simon Dack, M.D. Teaching Award
Mount Sinai Heart2012 - 2014
Scientific Program Committee
American College of Cardiology2011 -
Jess R Young, M.D. Teaching Award
Society for Vascular Medicine2010 -
Steering Committee
2010 - 2013
Chair American Heart Association Scientific Statement
2008 - 2010
Chair Writing Committee
American College of Cardiology2008 -
Master of the Society for Vascular Medicine
Society for Vascular Medicine2005 - 2007
Chair
Interdisciplinary Working Group on Atherosclerotic Peripheral Vascular Disease of the American Heart Association2004 - 2013
Associate Editor
Vascular Medicine2004 -
Present Chair
2002 - 2008
Peripheral Vascular Disease Steering Committee of the American Heart Association
1999 - 2001
President
Society for Vascular Medicine and Biology1991 -
Fellow
American College of Cardiology1991 -
Fellow
Society of Vascular Medicine and Biology1987 -
Fellow
American College of Physicians1983 - 1984
Outstanding Teacher Award
Department of Medicine the Western Pennsylvania Hospital
Publications
Olin JW. Thromboangiitis Obliterans (Buerger's Disease). N Engl J Med 2000; 343: 864-869.
Slovut DP, Olin JW. Fibromuscular Dysplasia. N Engl J Med 2004; 350: 1862-71.
Olin JW. Society for Vascular Medicine and Biology Presidential Address. A vision for the . Vasc Med 2000; 5: 205-207.
Massullo-LaPerna L, Olin JW, Goines D, Ouriel K. Ultrasound guided thrombin injection for the. Circulation 2000; 102: 2391-5.
Hirsch AT, Criqui MH, Treat-Jacobson D, Regensteiner JG, Creager MA, Olin JW, Krook SH, Hunninghake DB, Comerota AJ, Walsh ME, McDermott MM, Hiatt WR. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 2001; 286: 1317-1324.
Olin JW. Is fibromuscular dysplasia a single disease?. Circulation 2012 Dec; 126(25).
Kim ES, Olin JW, Froehlich JB, Gu X, Bacharach JM, Gray BH, Jaff MR, Katzen BT, Kline-Rogers E, Mace PD, Matsumoto AH, McBane RD, White CJ, Gornik HL. Clinical manifestations of fibromuscular dysplasia vary by patient sex: a report of the United States registry for fibromuscular dysplasia. Journal of the American College of Cardiology 2013 Nov; 62(21).
Del Conde I, Galin ID, Trost B, Kang J, Lookstein R, Woodward M, Gustavson S, Cambria RP, Jaff MR, Olin JW. Renal artery duplex ultrasound criteria for the detection of significant in-stent restenosis. Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 2013 Oct;.
Olin JW, Sealove BA. Diagnosis, management, and future developments of fibromuscular dysplasia. Journal of vascular surgery 2011 Mar; 53(3).
Creager MA, Olin JW, Belch JJ, Moneta GL, Henry TD, Rajagopalan S, Annex BH, Hiatt WR. Effect of hypoxia-inducible factor-1alpha gene therapy on walking performance in patients with intermittent claudication. Circulation 2011 Oct; 124(16).
Olin JW, Allie DE, Belkin M, Bonow RO, Casey DE, Creager MA, Gerber TC, Hirsch AT, Jaff MR, Kaufman JA, Lewis CA, Martin ET, Martin LG, Sheehan P, Stewart KJ, Treat-Jacobson D, White CJ, Zheng ZJ, Masoudi FA. ACCF/AHA/ACR/SCAI/SIR/SVM/SVN/SVS 2010 performance measures for adults with peripheral artery disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on performance measures, the American College of Radiology, the Society for Cardiac Angiography and Interventions, the Society for Interventional Radiology, the Society for Vascular Medicine, the Society for Vascular Nursing, and the Society for Vascular Surgery (Writing Committee to Develop Clinical Performance Measures for Peripheral Artery Disease). Circulation 2010 Dec; 122(24).
Olin JW, Froehlich J, Gu X, Bacharach JM, Eagle K, Gray BH, Jaff MR, Kim ES, Mace P, Matsumoto AH, McBane RD, Kline-Rogers E, White CJ, Gornik HL. The United States Registry for Fibromuscular Dysplasia: results in the first 447 patients. Circulation 2012 Jun; 125(25).
Weinberg MD, Lau JF, Rosenfield K, Olin JW. Peripheral artery disease. Part 2: medical and endovascular treatment. Nature reviews. Cardiology 2011 Aug; 8(8).
Mohler ER, Gornik HL, Gerhard-Herman M, Misra S, Olin JW, Zierler RE, Wolk MJ, Mohler ER. ACCF/ACR/AIUM/ASE/ASN/ICAVL/SCAI/SCCT/SIR/SVM/SVS/SVU [corrected] 2012 appropriate use criteria for peripheral vascular ultrasound and physiological testing part I: arterial ultrasound and physiological testing: a report of the American College of Cardiology Foundation appropriate use criteria task force, American College of Radiology, American Institute of Ultrasound in Medicine, American Society of Echocardiography, American Society of Nephrology, Intersocietal Commission for the Accreditation of Vascular Laboratories, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, Society for Interventional Radiology, Society for Vascular Medicine, Society for Vascular Surgery, [corrected] and Society for Vascular Ultrasound. [corrected]. Journal of the American College of Cardiology 2012 Jul; 60(3).
Nead KT, Zhou M, Diaz Caceres R, Olin JW, Cooke JP, Leeper NJ. Walking impairment questionnaire improves mortality risk prediction models in a high-risk cohort independent of peripheral arterial disease status. Circulation. Cardiovascular quality and outcomes 2013 May; 6(3).
Nead KT, Cooke JP, Olin JW, Leeper NJ. Alternative ankle-brachial index method identifies additional at-risk individuals. Journal of the American College of Cardiology 2013 Aug; 62(6).
Weinberg I, Keyes MJ, Giri J, Rogers KR, Olin JW, White CJ, Jaff MR. Blood pressure response to renal artery stenting in 901 patients from five prospective multicenter FDA-approved trials. Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 2013 Oct;.
Lau JF, Weinberg MD, Olin JW. Peripheral artery disease. Part 1: clinical evaluation and noninvasive diagnosis. Nature reviews. Cardiology 2011 Jul; 8(7).
White CJ, Olin JW. Diagnosis and management of atherosclerotic renal artery stenosis: improving patient selection and outcomes. Nature clinical practice. Cardiovascular medicine 2009 Mar; 6(3).
Weinberg MD, Olin JW. Stenting for atherosclerotic renal artery stenosis: one poorly designed trial after another. Cleveland Clinic journal of medicine 2010 Mar; 77(3).
Clinical Trials
Industry Relationships
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Olin during 2012 and/or 2013. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Scientific Advisory Board:
- Novartis; Pluristem Therapeutics Inc.
Other Activities: Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership.
- AstraZeneca; Pluristem Therapeutics Inc.
Equity (Stock or stock options valued at greater than 5% ownership of a publicly traded company or equity of any value in a privately held company)
- Northwind Medical
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website at http://icahn.mssm.edu/about-us/services-and-resources/faculty-resources/handbooks-and-policies/faculty-handbook. Patients may wish to ask their physician about the activities they perform for companies.
Faculty Practice Associates Floor 3
5 East 98th Street
New York, NY 10029
5 East 98th Street, 3rd Floor
New York, NY 10029
Fax: 212-241-5107
- Monday
- Tuesday
- Wednesday 9:00am - 6:00pm
- Thursday
- Friday 8:00am - 12:30pm
- Spanish
- Aetna U.S. Healthcare
- Beech Street
- CarePlus, LLC
- CenterCare, Inc.
- Cigna
- Devon Health Services
- Empire Blue Cross/Blue Shield
- Fidelis Care NY
- First Health
- Group Health Insurance, Inc.
- Health Insurance Plan (HIP)
- Healthfirst
- Island Group
- Local 1199
- Magnacare
- Medicaid
- Medicaid New Jersey
- Medicare
- MetroPlus Health Plan
- MultiPlan, Inc.
- Neighborhood Health Providers, LLC
- Oxford Health Plans
- PHS/Healthnet/Guardian
- Pomco
- Private Healthcare Systems (PHCS)
- Travel Care Services
- United Health Care Empire Plan
- United Healthcare
- Master Card
- Visa
- Personal Check
- Cash